Table 3.
Pooled analyses of Poisson-adjusted rate ratios for demographic and clinical characteristics associated with COVID-19-related hospitalisation or death among individuals who received booster doses
| Both vaccines adjusted rate ratio (95% CI) | mRNA-1273 adjusted rate ratio (95% CI) | BNT162b2 adjusted rate ratio (95% CI) | |
|---|---|---|---|
| Time since vaccination | |||
| 3–5 weeks after booster dose | 1·00 (ref) | 1·00 (ref) | 1·00 (ref) |
| 6–8 weeks after booster dose | 1·09 (0·97–1·23) | 0·96 (0·77–1·20) | 1·10 (0·95–1·27) |
| ≥9 weeks after booster dose | 1·20 (1·07–1·35) | 1·11 (0·87–1·41) | 1·11 (0·98–1·27) |
| Sex | |||
| Female | 1·00 (ref) | 1·00 (ref) | 1·00 (ref) |
| Male | 1·23 (1·20–1·26) | 1·04 (0·95–1·13) | 1·26 (1·23–1·29) |
| Age | |||
| 18–49 years | 1·00 (ref) | 1·00 (ref) | 1·00 (ref) |
| 50–54 years | 0·90 (0·85–0·96) | 0·81 (0·68–0·96) | 0·91 (0·85–0·97) |
| 55–59 years | 0·91 (0·85–0·97) | 0·85 (0·72–1·01) | 0·90 (0·84–0·96) |
| 60–64 years | 1·01 (0·95–1·07) | 0·97 (0·82–1·15) | 0·98 (0·92–1·04) |
| 65–69 years | 1·21 (1·14–1·28) | 1·50 (1·27–1·78) | 1·10 (1·03–1·17) |
| 70–74 years | 1·46 (1·39–1·53) | 1·91 (1·60–2·28) | 1·31 (1·24–1·38) |
| 75–79 years | 1·95 (1·86–2·05) | 2·98 (2·49–3·58) | 1·73 (1·65–1·82) |
| ≥80 years | 3·60 (3·45–3·75) | 5·52 (4·73–6·43) | 3·19 (3·06–3·33) |
| Ethnicity* | |||
| White | 1·00 (ref) | 1·00 (ref) | 1·00 (ref) |
| Asian | 0·89 (0·83–0·96) | 1·02 (0·80–1·31) | 0·88 (0·82–0·94) |
| Black | 0·99 (0·88–1·10) | 1·20 (0·80–1·81) | 0·95 (0·84–1·07) |
| Mixed | 0·99 (0·85–1·15) | 1·35 (0·85–2·16) | 0·94 (0·80–1·11) |
| Other | 1·21 (1·03–1·41) | 1·36 (0·81–2·27) | 1·16 (0·98–1·38) |
| Unknown | 0·94 (0·89–0·98) | 0·78 (0·65–0·94) | 0·95 (0·90–1·00) |
| Socioeconomic deprivation status† | |||
| 5 (least deprived) | 1·00 (ref) | 1·00 (ref) | 1·00 (ref) |
| 4 | 1·07 (1·04–1·11) | 1·21 (1·06–1·38) | 1·06 (1·02–1·10) |
| 3 | 1·14 (1·10–1·18) | 1·14 (0·99–1·30) | 1·13 (1·08–1·17) |
| 2 | 1·20 (1·15–1·24) | 1·32 (1·16–1·51) | 1·18 (1·13–1·22) |
| 1 (most deprived) | 1·35 (1·29–1·40) | 1·45 (1·26–1·66) | 1·33 (1·27–1·38) |
| BMI‡ | |||
| <18·5 | 1·42 (1·32–1·52) | 1·01 (0·76–1·33) | 1·46 (1·35–1·57) |
| 18·5–24·9 | 1·00 (ref) | 1·00 (ref) | 1·00 (ref) |
| 25·0–29·9 | 0·87 (0·84–0·90) | 0·82 (0·73–0·92) | 0·88 (0·85–0·90) |
| 30·0–34·9 | 0·88 (0·85–0·92) | 0·92 (0·80–1·05) | 0·88 (0·85–0·92) |
| 35·0–39·9 | 0·97 (0·92–1·02) | 0·92 (0·76–1·10) | 0·97 (0·92–1·02) |
| ≥40·0 | 1·13 (1·06–1·21) | 1·08 (0·87–1·34) | 1·13 (1·05–1·20) |
| Unknown | 1·54 (1·44–1·64) | 1·08 (0·86–1·36) | 1·60 (1·50–1·71) |
| Number of risk groups‡ | |||
| 0 | 1·00 (ref) | 1·00 (ref) | 1·00 (ref) |
| 1 | 1·98 (1·90–2·06) | 1·82 (1·61–2·06) | 1·97 (1·88–2·06) |
| 2 | 3·35 (3·21–3·50) | 2·83 (2·46–3·25) | 3·34 (3·19–3·50) |
| 3 | 4·78 (4·56–5·00) | 4·04 (3·45–4·73) | 4·75 (4·53–4·99) |
| 4 | 6·34 (6·03–6·66) | 5·98 (4·98–7·18) | 6·24 (5·92–6·57) |
| ≥5 | 9·51 (9·07–9·97) | 10·03 (8·40–11·99) | 9·34 (8·89–9·81) |
| Number of risk groups by British National Formulary British National Formulary chapters§ | |||
| 0 | 1·00 (ref) | 1·00 (ref) | 1·00 (ref) |
| 1 | 1·25 (0·91–1·72) | 1·22 (0·66–2·26) | 1·27 (0·88–1·83) |
| 2 | 2·33 (1·75–3·09) | 1·46 (0·77–2·76) | 2·58 (1·86–3·56) |
| 3 | 2·68 (2·01–3·57) | 2·76 (1·55–4·91) | 2·66 (1·90–3·71) |
| 4 | 3·72 (2·78–4·98) | 2·79 (1·51–5·16) | 4·08 (2·93–5·69) |
| 5 | 5·58 (4·17–7·46) | 4·92 (2·65–9·13) | 5·70 (4·09–7·95) |
| ≥6 | 6·46 (4·87–8·58) | 7·26 (4·07–12·97) | 6·28 (4·53–8·70) |
| Urban-rural index† | |||
| Urban | 1·00 (ref) | 1·00 (ref) | 1·00 (ref) |
| Rural | 0·91 (0·88–0·94) | 0·99 (0·89–1·11) | 0·91 (0·88–0·94) |
| Interval between primary vaccine doses | |||
| 3–6 weeks | 1·00 (ref) | 1·00 (ref) | 1·00 (ref) |
| 7–8 weeks | 0·98 (0·92–1·05) | 1·01 (0·75–1·36) | 1·01 (0·94–1·08) |
| 9–10 weeks | 1·09 (1·03–1·15) | 1·08 (0·81–1·43) | 1·10 (1·05–1·16) |
| 11–12 weeks | 1·10 (1·05–1·16) | 1·19 (0·90–1·58) | 1·12 (1·06–1·18) |
| ≥13 weeks | 1·76 (1·64–1·90) | 1·73 (1·25–2·39) | 1·82 (1·68–1·96) |
| Number of previous RT-PCR tests | |||
| 0 | 1·00 (ref) | 1·00 (ref) | 1·00 (ref) |
| 1 | 1·29 (1·20–1·39) | 1·20 (1·00–1·44) | 1·33 (1·23–1·44) |
| 2 | 1·29 (1·19–1·40) | 1·44 (1·16–1·79) | 1·28 (1·17–1·40) |
| 3–4 | 2·56 (2·35–2·80) | 2·52 (1·99–3·19) | 2·59 (2·36–2·86) |
| 5–9 | 4·40 (3·98–4·86) | 5·83 (4·42–7·69) | 4·43 (3·94–4·99) |
| ≥10 | 4·63 (4·13–5·19) | 3·86 (2·59–5·77) | 4·67 (4·10–5·31) |
| History of SARS-CoV-2 infection | |||
| No previous infection | 1·00 (ref) | 1·00 (ref) | 1·00 (ref) |
| <3 months | 0·67 (0·54–0·84) | 0·44 (0·21–0·94) | 0·69 (0·54–0·87) |
| 3–5 months | 0·91 (0·73–1·12) | 0·99 (0·49–1·99) | 0·89 (0·71–1·12) |
| 6–8 months | 0·70 (0·51–0·96) | 1·04 (0·45–2·38) | 0·75 (0·53–1·06) |
| ≥9 months | 0·41 (0·29–0·58) | 0·34 (0·08–1·36) | 0·41 (0·29–0·58) |
Overall estimates are shown as well as those stratified by type of vaccine at second dose.
*
England and Wales.
†
Because of the little data on unknown status, these data were omitted.
‡
England, Scotland, and Wales.
§
Northern Ireland only.